Article Text

Download PDFPDF

Treatment of neonatal abstinence syndrome
Free
  1. K Johnson1,
  2. C Gerada2,
  3. A Greenough1
  1. 1Children Nationwide Regional Neonatal Intensive Care Centre, Department of Child Health, King’s College Hospital, London SE5 9RS, UK
  2. 2The Hurley Clinic, Kennington Lane, London SE11 4HJ, UK
  1. Correspondence to:
    Dr Johnson, Department of Child Health, 4th floor, Ruskin Wing, King’s College Hospital, London SE5 9RS, UK:
    kathryn.2.johnson{at}kcl.ac.uk

Abstract

Neonatal abstinence syndrome (NAS) is suffered by infants withdrawing from substances on which they have become physically dependent after in utero exposure. They may require prolonged treatment and spend weeks or even months in hospital. A wide range of drugs have been used to treat NAS. The efficacy of few, however, have been adequately investigated. Evidence suggests that opioids are the most appropriate, at least in infants exposed to diamorphine or methadone. In all “head to head” trials, diazepam has been shown to be ineffective. Morphine and methadone are currently the most commonly prescribed opioids to treat NAS, but randomised trials have not been undertaken to determine which is the more beneficial. Many infants with NAS have been exposed to multiple substances in utero. Further research is required into whether a single opiate or a multiple drug regimen is the best option for such patients.

  • neonatal abstinence syndrome
  • drug abuse
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.